Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2852W HIGH $2.60
Volume
23.70 K
Value Traded
41.24 K
Short % Float
3.93%
0%Week
-24.66%1 Month
+143.48%3 Month
+133.33%6 Month
-97.3%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.44 M
EPS (TTM)
-11.40
P/E Ratio
-
Ent. Value
-2.63 M
Total Shares
4.43 M
Float Shares
2.98 M
Insiders
32.76%
Institutions
12.44%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
SKYE Catalyst Timeline
Dated clinical, regulatory and corporate events for Skye Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Skye Bioscience, Inc.
295Total events
11Upcoming
61Tier-1 (high impact)
2015 to 2028Coverage
Upcoming catalysts 2
Event history 50
▼Equity OfferingCorporate
Series A financing of $36 million expected to close within next few days
◆Quarterly UpdateNimacimabCorporate
CBeyond Phase 2a results to be described in 10-Q filed later today
obesity/overweightsource ↗
◆Full ResultsNimacimabClinical Data
Full topline reporting of Phase 2a extension data including monotherapy and 13-week follow-up
obesitysource ↗
◆Topline ReadoutNimacimabClinical Data
CBeyond Phase 2a topline results to 52 weeks including 13-week off-therapy follow-up expected Q3 2026
obesitysource ↗
◆Trial InitiationNimacimabTrial
Phase 2b (CBeyond 2) trial launch targeted for Q3 2026
obesitysource ↗
▲Safety Data UpdateNimacimabClinical Data
CRC approved opening of Cohort 2 based on favorable safety data from first four participants in Cohort 1
obesitysource ↗
▲Trial InitiationNimacimabTrial
Initiated enrollment of Cohort 1 of CBeyond Expansion Study
obesitysource ↗
▲Partnership / LicenseNimacimabCorporate
Engaged Lilly Catalyze360 for strategic guidance on TPP and Phase 2b trial design
obesitysource ↗
◆Oral PresentationNimacimabPresentation
Presentation at GLP-1-Based Therapeutics Summit
obesitysource ↗
▲First Patient DosedNimacimabTrial
First patient dosed in Part C expansion study of nimacimab higher-dose IV cohorts
obesitysource ↗
◆FDA Feedback ReceivedNimacimabFDA Meeting
Received written FDA feedback from Type C meeting on Phase 2b trial design
obesitysource ↗
◆Enrollment MilestoneNimacimabTrial
Complete enrollment across Cohorts 1 and 2 of CBeyond Expansion Study
obesitysource ↗
◆Oral PresentationNimacimabPresentation
Present nimacimab preclinical data at scientific/medical conferences
obesity, overweightsource ↗
◆R&D DayNimacimabPresentation
Analyst event in conjunction with ADA Scientific Sessions
obesity, overweightsource ↗
◆Manufacturing MilestoneNimacimabCMC / Inspection
Complete feasibility work for high-concentration nimacimab formulation
obesitysource ↗
◆Quarterly UpdateCorporate
2025 Q4 and full-year financial results and business update conference call
▲Trial InitiationNimacimabTrial
Initiated higher-dose CBeyond Expansion Study (Part C) with 400 mg and 600 mg IV cohorts
obesity, overweightsource ↗
◆FDA Feedback ReceivedNimacimabFDA Meeting
Received written FDA Type C meeting minutes
obesity, overweightsource ↗
▲Preclinical PoCNimacimabPreclinical
Proof-of-concept preclinical data validates antigen-peptide conjugate platform (nimacimab-GLP1RA)
obesity, overweightsource ↗
▲Partnership / LicenseNimacimabCorporate
Licensed ENHANZE drug delivery technology from Halozyme
obesity, overweightsource ↗
▲Interim AnalysisNimacimabTrial
Interim Phase 2a extension study data at 52 weeks showed 22.3% total weight loss with no plateau
obesitysource ↗
▲Topline ReadoutNimacimabClinical Data
Topline 26-week data from CBeyond Phase 2a study showed 13% additive weight loss on top of semaglutide
obesitysource ↗
◆Poster PresentationNimacimabPresentation
Poster presentation at Keystone Obesity Conference on nimacimab DIO mouse model studies
obesitysource ↗
◆Poster PresentationNimacimabPresentation
Poster presentation at Keystone Obesity Conference on nimacimab alone or in combination with tirzepatide
obesitysource ↗
◆IP Litigation RulingIP / Competition
Lead plaintiff deadline for class action securities lawsuit
◆Short Report ActivistCorporate
Lead plaintiff deadline to request appointment in class action lawsuit
◆Interim AnalysisNimacimabTrial
CBeyond Phase 2a 26-week extension data update and interim results expected Q1 2026
obesitysource ↗
◆Type C MeetingNimacimabFDA Meeting
Type C meeting to finalize Phase 2b plan expected Q1 2026
obesitysource ↗
▲Full ResultsNimacimabClinical Data
Previously reported CBeyond interim extension data (52-week combination update)
obesitysource ↗
▲Manufacturing MilestoneNimacimabCMC / Inspection
Completed compatibility and in-use study with ENHANZE
obesitysource ↗
▲Fast Track DesignationRXC008Designation
RXC008 granted FDA Fast Track designation in January 2026
fibrostenotic Crohn's diseasesource ↗
▼Short Report ActivistCorporate
Class action lawsuit filed against Skye Bioscience alleging misleading statements about nimacimab
▼Short Report ActivistCorporate
Class action lawsuit filed against Skye Bioscience alleging misstatements about nimacimab
▼IP Litigation RulingIP / Competition
Securities class action lawsuit filed against Skye Bioscience
▼Short Report ActivistCorporate
Class action lawsuit filed against Skye Bioscience alleging securities law violations
▲DSMB ReviewNimacimabTrial
CBeyond Phase 2a DMC meeting demonstrated favorable safety profile
obesitysource ↗
▼Short Report ActivistCorporate
Class action lawsuit filed against Skye Bioscience alleging misstatements about nimacimab
Past FDA Catalysts and PDUFA Decisions
How SKYE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-03-31 | nimacimab | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D29 / 100
Pipeline Score
$2M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 72%
Micro Cap(rank 474 of 658)
Percentile Rank
Skye Bioscience, Inc. faces pipeline headwinds (29/100), with $670M risk-adjusted pipeline value, led by Nimacimab in Obesity (Phase 2), but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nimacimab Monoclonal antibodyNCT06577090 | Obesity | Phase 2 | ACTIVE NOT_RECRUITING | 136 | Feb 28, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every SKYE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| nimacimab | obesity and related conditions | Phase 2b | 2026-05-12 | approximately 3% incremental weight-loss benefit versus semaglutide alone at 26 weeks; 22.3% mean weight loss at 52 weeksRead More | UPDATE · Skye Bioscience Reports First Quarter 2026 Financial Results and Business UpdateRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| 5AM Partners VII, LLC10% Owner | Sell | -114,851 | $1.61 | 09/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SKYE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0 % | 1.09 M | 1.58 M |
SKYE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SKYE ranks across every disease it competes in
Competitive Position is a premium feature
See how SKYE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSKYE News
SKYE▼ -7.3%on this news· ran to -43% by day 3
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
Skye Bioscience and Redx Pharma have announced a definitive transaction agreement, leading to the formation of a new company, Fibrx Therapeutics, which will focus on fibrosis treatments. The combined entity will operate under the leadership of Redx's management team and will pursue the development of RXC008, a pan-ROCK inhibitor for fibrostenotic Crohn's disease. The transaction includes $125 million in financing to support operations through the planned Phase 2 clinical trial.
Read more →SKYE▲ +6%on this news
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
Skye Bioscience has announced the unanimous approval by its Cohort Review Committee to open enrollment for Cohort 2 in the CBeyond Part C Expansion Study. This decision is based on favorable safety data from the initial four participants treated in Cohort 1. The study is focused on the safety of nimacimab monotherapy, with a comparison against a placebo. The initial findings have shown no reported neuropsychiatric adverse events, allowing for a dosage escalation to 600 mg IV in the new cohort.
Read more →SKYE▼ -7.6%on this news
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience reported its Q1 2026 financial results, highlighting the initiation of the CBeyond Expansion Study and the upcoming review by the Cohort Review Committee. The company aims to advance nimacimab as a complementary therapy for obesity and related conditions. Financially, Skye holds $17.1 million in cash, which is expected to support operations through Q4 2026, despite a net loss of $12.5 million.
Read more →SKYESkye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience reported its Q1 2026 financial results, highlighting the initiation of the CBeyond Expansion Study and strategic partnerships for the development of nimacimab. The company aims to prepare for a Phase 2b trial, with topline data expected by Q4 2026. Despite a net loss, Skye remains focused on advancing its clinical programs.
Read more →SKYESkye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience will present at the GLP-1-Based Therapeutics Summit in Boston on April 16, 2026. The presentation will focus on their drug nimacimab, a monoclonal antibody designed to treat obesity without central nervous system side effects. The company is conducting a Phase 2a trial to evaluate the efficacy of nimacimab in combination with GLP-1 agonists.
Read more →SKYESkye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience has initiated treatment for the first patient in its Part C expansion study of nimacimab as part of the Phase 2a trial. This study aims to evaluate higher doses of nimacimab to inform dose selection for a potential Phase 2b trial. Previous studies have shown promising weight loss results when combined with semaglutide, and the company has received regulatory feedback from the FDA. However, enrollment for the second dosing cohort is contingent on the safety review of the first cohort's participants.
Read more →SKYE▲ +11%on this news
2025 Year-end & Q4 Financial Results and Update
The article discusses the financial results for the year-end and Q4 of 2025 for SKYE. It mentions the publication date of March 10, 2026, and includes references to related documents such as a news release and a conference call presentation. However, specific financial details or insights are not provided in the text.
Read more →SKYE▲ +10.3%on this newsshared move
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience reported its financial results for Q4 and full year 2025, detailing key developments in its programming aimed at obesity treatment. The company has initiated a higher-dose CBeyond Expansion Study targeting improved safety and pharmacokinetics for nimacimab, alongside promising results from its Phase 2a trial in combination with semaglutide leading to significant weight loss. Skye is utilizing FDA feedback to refine its Phase 2b trial design, suggesting a disciplined approach to dosage and effectiveness evaluation. Continued advancements in manufacturing processes support the potential for nimacimab's commercial supply and improved patient accessibility.
Read more →SKYESkye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Skye Bioscience, a clinical-stage biotechnology company, will announce its 2025 financial results and business update on March 10, 2026. The announcement will be followed by a conference call to discuss the results. Skye is actively developing therapeutics for obesity, including a Phase 2a trial for nimacimab, a novel antibody.
Read more →SKYE▼ -7.9%on this news· ran to -21% by day 3
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience announced positive interim results from the Phase 2a CBeyond study, showing that patients receiving nimacimab in combination with semaglutide achieved a mean weight loss of 22.3% after 52 weeks. The therapy was well tolerated, with no serious adverse events reported. The results suggest potential for further weight loss with optimized dosing in future trials.
Read more →SKYE▼ -7.9%on this news· ran to -21% by day 3shared move
Developing Innovative Medicines to Treat Obesity and Other Metabolic Diseases February 2026 Nasdaq: SKYE 2 02 6 Sk ye B io sc ie nc e, In c. This presentation ("Presentation") has been prepared solely for general infor
Skye Bioscience, Inc. is advancing its innovative medication, nimacimab, aimed at treating obesity and metabolic diseases. Featuring a combination therapy with semaglutide, recent Phase 2a data show nimacimab resulted in significant weight loss outcomes, improving treatment tolerability. However, the therapy remains in investigational phases pending regulatory review, and the company has noted potential risks linked to capital constraints and clinical trials.
Read more →SKYESkye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Skye Bioscience presented findings on its peripherally-restricted CB1 inhibitor, nimacimab, at the Keystone Obesity Conference. The studies suggest that nimacimab combined with lower doses of incretin agonists could provide a safer and effective treatment for obesity. The company is conducting a Phase 2a trial to further evaluate nimacimab's efficacy and safety.
Read more →SKYENimacimab Enhances Incretin Therapies in DIO Mouse Model
At the Keystone conference, it was reported that Nimacimab significantly enhances weight loss when used with tirzepatide, even at lower doses. The treatment led to durable weight loss post-discontinuation and improved rebound profiles. Notably, caloric restriction was not the main factor driving the weight loss associated with Nimacimab.
Read more →SKYESkye Bioscience to Present Poster at Keystone Obesity Conference
Skye Bioscience will present a poster on its CB1-inhibitor antibody, nimacimab, at the Keystone Obesity Conference. The presentation will explore nimacimab's efficacy alone and in combination with tirzepatide in a mouse model of diet-induced obesity. This innovative approach aims to limit neuropsychiatric side effects associated with traditional CB1-targeting drugs. Skye is also conducting a Phase 2a clinical trial for nimacimab in obesity.
Read more →SKYESkye Provides 2026 Corporate Outlook
Skye Bioscience has outlined its corporate outlook for 2026, focusing on advancing its lead candidate, nimacimab, through various clinical trials and milestones. Key upcoming events include a data update on Phase 2a trials expected in Q1 2026 and the design of a Phase 2b trial targeting combination therapies. Preliminary results indicate the potential for nimacimab to complement existing treatments for obesity, showcasing additive effects when used with semaglutide. Despite positive indicators, future progress depends on adequate funding and execution of planned clinical studies.
Read more →SKYEUnlocking Solutions to Deliver Higher Doses
The article discusses Skye Bioscience's efforts to develop solutions for delivering higher doses of treatments. It highlights the importance of addressing dosing challenges in bioscience, particularly in the context of obesity. The publication date indicates a recent focus on advancements in this area.
Read more →SKYEUsing Arecor’s Arestat Technology to Increase Drug Dosing
Skye Bioscience has announced the use of Arecor's Arestat technology to enhance drug dosing. This development was published on January 4, 2026. The article does not provide further details on the implications or applications of this technology in drug development.
Read more →SKYEWorking with Halozyme ENHANZE® Technology for Higher Dosing
Skye Bioscience has published an article discussing their collaboration with Halozyme to utilize ENHANZE® technology for higher dosing. This technology aims to enhance drug delivery and improve patient outcomes. The article highlights the potential benefits of this partnership in the bioscience field, particularly concerning obesity treatment.
Read more →SKYECharacterizing/Advancing Higher-exposure Dosing
Skye's Project Ascend is a 90-day initiative focused on validating higher-exposure dosing for nimacimab. The project aims to enhance the clinical and translational evidence supporting the role of peripheral CB1 inhibition in treating obesity. This effort represents a significant step forward in addressing obesity through innovative dosing strategies.
Read more →SKYE▼ -7.6%on this newsshared move
CEO 2025 Year in Review
In the 2025 Year in Review, CEO Punit Dhillon outlines Skye Bioscience's achievements over the past year and shares insights into the strategic plans for 2026. The review emphasizes the company's commitment to advancing in the bioscience sector, particularly in addressing obesity. Skye aims to build on its successes as it moves into the new year.
Read more →About Skye Bioscience, Inc.
Headquarters11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next SKYE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime